Broadview Ventures, the family office of the Leducq Family Trust and a new investor in DecImmune, and venture capital firm HealthCare Ventures joined Astellas in the round.

In a regulatory filing last month, Obalon said it had raised $5m from one investor and has now disclosed that AmorePacific Ventures had taken a strategic stake in the company.

Australia-based biotech PolyActiva receives AUS$9.2m ($9.5m) series B from a consortium of new and existing investors to develop glaucoma and osteoarthritis treatments.

The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.

The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.

Through this collaboration, the two organisations will mutually-selected CVI research and development projects with the goal of commercializing them and resulting intellectual property.

Through this collaboration, the two organisations will mutually-selected CVI research and development projects with the goal of commercializing them and resulting intellectual property.